Skelaxin (metaxalone) and Flexeril (cyclobenzaprine) both relax muscles, but they achieve this through different pathways. Skelaxin’s exact mechanism isn’t fully understood, but it’s believed to act within the central nervous system, reducing muscle spasms by affecting polysynaptic reflexes. It doesn’t directly relax the muscles themselves; instead, it modifies the signals sent to them.
Skelaxin’s Action
Studies suggest Skelaxin potentially interacts with various neurotransmitters, impacting the transmission of pain signals and reducing muscle spasticity. This makes it a relatively specific muscle relaxant, with fewer reported side effects affecting other bodily systems compared to Flexeril.
Flexeril’s Action
Flexeril, on the other hand, is a centrally acting muscle relaxant with a closer relationship to tricyclic antidepressants. It blocks the reuptake of norepinephrine and serotonin, thus affecting both muscle relaxation and mood. This dual action explains why Flexeril carries a higher risk of side effects like drowsiness and dry mouth.
| Primary Mechanism | Affects polysynaptic reflexes in the CNS | Blocks norepinephrine and serotonin reuptake |
| Side Effect Profile | Generally milder; less impact on other systems | More pronounced side effects, including drowsiness and dry mouth |
| Chemical Class | Muscle relaxant (exact mechanism unclear) | Structurally related to tricyclic antidepressants |
Consequently, the choice between Skelaxin and Flexeril often depends on individual patient needs and tolerance for specific side effects. A physician should always be consulted before starting either medication.
